Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
7.98
-0.30 (-3.62%)
At close: Mar 9, 2026, 4:00 PM EDT
8.00
+0.02 (0.25%)
After-hours: Mar 9, 2026, 4:29 PM EDT
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,596,410
Market Cap
18.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Citius Pharmaceuticals | 23 |
| Reviva Pharmaceuticals Holdings | 14 |
| VYNE Therapeutics | 13 |
| Genenta Science | 13 |
| Allarity Therapeutics | 7 |
| Intensity Therapeutics | 7 |
| Lexaria Bioscience | 7 |
| NanoViricides | 7 |
CVKD News
- 7 days ago - Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - GlobeNewsWire
- 13 days ago - Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement - GlobeNewsWire
- 2 months ago - Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor - GlobeNewsWire
- 2 months ago - Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - Accesswire
- 2 months ago - Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - Accesswire
- 2 months ago - Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 - GlobeNewsWire
- 3 months ago - Cadrenal's Quiet Expansion Play Is Starting to Get Loud - Accesswire
- 3 months ago - Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - Accesswire